Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access |

Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc |

Journal website http://www.gastrores.org |

Original Article

Volume 7, Number 5-6, December 2014, pages 123-130

**Impact of Interleukin 28B Genotype on the Virological Responses in Chronic Hepatitis C Treatment**

Tables

BMI: body mass index; ALT: alanin aminotransferase; SD: standart deviation; CI: confidence interval. ^{a}Logarithmic transformation (base 10) was applied. Confidence intervals of geometric mean are computed using 1,000 bootstrap samples. ^{b}Genotypes were determined in 167 patients. ^{c}152 patients with liver biopsy, evaluated based on the Ishak score. | |

Gender, n (%) | |

Female | 121 (65.1) |

Male | 65 (34.9) |

Age (years), mean ± SD | 55.6 ± 10 |

BMI (kg/m^{2}), mean ± SD | 27.3 ± 4.6 |

Normal weight (< 25 kg/m^{2}), n (%) | 55 (29.6) |

Overweight (25-29.9 kg/m^{2}), n (%) | 95 (51.1) |

Obese (≥ 30 kg/m^{2}), n (%) | 36 (19.4) |

Viral load at baseline (IU/mL), geometric mean (95% CI)^{a} | 854,053 (663,578 - 1,087,754) |

< 400,000 (IU/mL), n (%) | 56 (30.1) |

≥ 400,000 (IU/mL), n (%) | 130 (69.9) |

Genotype, n (%)^{b} | |

Genotype 1b | 145 (86.8) |

Genotype 4 | 22 (13.2) |

Baseline ALT levels (IU/L), median (first to third quartiles) | 49.0 (34.0 - 69.0) |

Liver necroinflammation^{c}, median (first to third quartiles) | 5.5 (4.0 - 8.0) |

Liver fibrosis^{c}, median (first to third quartiles) | 2.0 (1.0 - 3.0) |

Distribution of liver fibrosis, n (%) | |

Mild (Ishak staging score 0 - 2) | 107 (70.5) |

Moderate (Ishak staging score 3 - 4) | 35 (23.0) |

Severe (Ishak staging score 5 - 6) | 10 (6.5) |

Variables | C/C (n = 42) | C/T (n = 98) | T/T (n = 46) | P |
---|---|---|---|---|

BMI: body mass index; ALT: alanin aminotransferase; SD: standart deviation; CI: confidence interval. ^{a}Logarithmic transformation (base 10) was applied. Confidence intervals of geometric mean are computed using 1,000 bootstrap samples. ^{b}Genotypes were determined in 167 patients. ^{c}Cases with liver biopsy were evaluated based on Ishak score. ^{d}30 patients. ^{e}83 patients. ^{f}39 patients. Different superscripts in a row (x, y) indicate statistically significant difference between groups. | ||||

Age (years), mean ± SD | 53.3 ± 11.2 | 55.7 ± 9.2 | 57.5 ± 10.2 | 0.147 |

Male, n (%) | 17 (40.5) | 31 (31.6) | 17 (37) | 0.571 |

BMI (kg/m^{2}), mean ± SD | 26.9 ± 4.3 | 27.7 ± 4.7 | 26.9 ± 4.6 | 0.446 |

Viral load at baseline (IU/mL), geometric mean (95% CI)^{a} | 987,812 (571,056 - 1,811,751) | 905,147 (648,435 - 1,296,846) | 660,740 (406,456 - 1,055,059) | 0.503 |

Patients with baseline viral load < 400,000 IU/mL, n (%) | 18 (42.9) | 21 (21.4) | 16 (34.8) | 0.020 |

Genotype 1b^{b}, n (%) | 37 (97.4) | 73 (83.9) | 35 (83.3) | 0.091 |

Genotype 4^{b}, n (%) | 1 (2.6) | 14 (16.1) | 7 (16.7) | |

Baseline ALT levels (IU/L), median (first to third quartiles) | 50.0 (34.0 - 83.0)^{xy} | 44.0 (29.0 - 59.0)^{x} | 57.5 (37.0-87.0)^{y} | 0.006 |

Liver necroinflammation^{c}, median (first to third quartiles) | 6.0 (4.0 - 6.0) | 5.0 (4.0 - 8.0) | 6.0 (4.0 - 8.0) | 0.669 |

Liver fibrosis^{c}, median (first to third quartiles) | 1.0 (1.0 - 2.0)^{x} | 2.0 (1.0 - 3.0)^{y} | 1.0 (1.0 - 3.0)^{xy} | 0.023 |

Distribution of liver fibrosis, n (%) | ||||

Mild (Ishak staging score 0 - 2) | 25 (83.3)^{d} | 53 (63.9)^{e} | 29 (74.4)^{f} | 0.236 |

Moderate (Ishak staging score 3 - 4) | 5 (16.7)^{d} | 23 (27.7)^{e} | 7 (17.9)^{f} | |

Severe (Ishak staging score 5 - 6) | 0 (0.0)^{d} | 7 (8.4)^{e} | 3 (7.7)^{f} |

IL28B | SVR (n = 83), n (%) | Non-response (n = 103), n (%) | P | OR (95% CI) | |
---|---|---|---|---|---|

SVR: sustained virologic response; OR: odds ratio; CI: confidence interval. | |||||

rs12979860 alleles | C | 98 (59) | 84 (41) | < 0.001 | - |

T | 68 (41) | 122 (59) | < 0.001 | ||

rs12979860 genotypes | CC | 28 (66.7) | 14 (33.3) | 0.001 | 1 |

CT | 42 (42.9) | 56 (57.1) | 0.38 (0.18 - 0.80) | ||

TT | 13 (28.3) | 33 (71.7) | 0.20 (0.08 - 0.49) |

Variables, n (%) | C/C (n = 42) | C/T (n = 98) | T/T (n = 46) | P |
---|---|---|---|---|

RVR: rapid virological response; cEVR: complete early virological response; EVR: early virological response; pEVR: partial early virological response; ETR: end-of-treatment response; SVR: sustained virological response; PR: partial response; NR: null response. ^{a}Five patients were not evaluated for RVR. | ||||

RVR | 23 (54.8) | 39 (41.9)^{a} | 18 (39.1) | 0.216 |

cEVR | 37 (88.1) | 57 (58.2) | 22 (47.8) | < 0.001 |

EVR (cEVR + pEVR) | 41 (97.6) | 71 (72.4) | 29 (63.0) | < 0.001 |

ETR | 38 (90.5) | 61 (62.2) | 26 (56.5) | 0.001 |

SVR | 28 (66.7) | 42 (42.9) | 13 (28.3) | 0.001 |

Relapse | 11 (26.2) | 20 (20.4) | 14 (30.4) | 0.400 |

PR | 1 (2.4) | 8 (8.2) | 3 (6.5) | 0.443 |

NR | 1 (2.4) | 25 (25.5) | 16 (34.8) | 0.001 |

Breakthrough | 1 (2.4) | 3 (3.1) | 0 (0.0) | 0.495 |